Cargando…
The investment case for folic acid fortification in developing countries
There is compelling evidence that neural tube defects can be prevented through mandatory folic acid fortification. Why, then, is an investment case needed? At the core of the answer to this question is the notion that governments and individuals have limited resources for which there are many compet...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887927/ https://www.ncbi.nlm.nih.gov/pubmed/29363765 http://dx.doi.org/10.1111/nyas.13527 |
_version_ | 1783312415929139200 |
---|---|
author | Hoddinott, John |
author_facet | Hoddinott, John |
author_sort | Hoddinott, John |
collection | PubMed |
description | There is compelling evidence that neural tube defects can be prevented through mandatory folic acid fortification. Why, then, is an investment case needed? At the core of the answer to this question is the notion that governments and individuals have limited resources for which there are many competing claims. An investment case compares the costs and benefits of folic acid fortification relative to alternative life‐saving investments and informs estimates of the financing required for implementation. Our best estimate is that the cost per death averted through mandatory folic acid fortification is $957 and the cost per disability‐adjusted life year is $14.90. Both compare favorably to recommended life‐saving interventions, such as the rotavirus vaccine and insecticide‐treated bed nets. Thus, there is a strong economic argument for mandatory folic acid fortification. Further improvements to these estimates will require better data on the costs of implementing fortification and on the costs of improving compliance where regulations are already in place. |
format | Online Article Text |
id | pubmed-5887927 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-58879272018-04-12 The investment case for folic acid fortification in developing countries Hoddinott, John Ann N Y Acad Sci Original Article There is compelling evidence that neural tube defects can be prevented through mandatory folic acid fortification. Why, then, is an investment case needed? At the core of the answer to this question is the notion that governments and individuals have limited resources for which there are many competing claims. An investment case compares the costs and benefits of folic acid fortification relative to alternative life‐saving investments and informs estimates of the financing required for implementation. Our best estimate is that the cost per death averted through mandatory folic acid fortification is $957 and the cost per disability‐adjusted life year is $14.90. Both compare favorably to recommended life‐saving interventions, such as the rotavirus vaccine and insecticide‐treated bed nets. Thus, there is a strong economic argument for mandatory folic acid fortification. Further improvements to these estimates will require better data on the costs of implementing fortification and on the costs of improving compliance where regulations are already in place. John Wiley and Sons Inc. 2018-01-24 2018-02 /pmc/articles/PMC5887927/ /pubmed/29363765 http://dx.doi.org/10.1111/nyas.13527 Text en © 2018 The Authors. Annals of the New York Academy of Sciences. The World Health Organization retains copyright and all other rights in the manuscript of this article as submitted for publication. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Hoddinott, John The investment case for folic acid fortification in developing countries |
title | The investment case for folic acid fortification in developing countries |
title_full | The investment case for folic acid fortification in developing countries |
title_fullStr | The investment case for folic acid fortification in developing countries |
title_full_unstemmed | The investment case for folic acid fortification in developing countries |
title_short | The investment case for folic acid fortification in developing countries |
title_sort | investment case for folic acid fortification in developing countries |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887927/ https://www.ncbi.nlm.nih.gov/pubmed/29363765 http://dx.doi.org/10.1111/nyas.13527 |
work_keys_str_mv | AT hoddinottjohn theinvestmentcaseforfolicacidfortificationindevelopingcountries AT hoddinottjohn investmentcaseforfolicacidfortificationindevelopingcountries |